SLC7A11 and metabolic syndrome: These data demonstrate that PT, an active Vitamin B5 derivative clinically approved for dyslipidemia,[19] stabilizes SLC7A11 by directly binding to PSMD14 and enhancing its deubiquitinating activity in MLO‐Y4 cells.